Abstract 2929
Background
The human microbiome has been suggested to be involved in the regulation of response to anticancer strategies, however, information about how commensal microbes in a cancer patient change during radiotherapy is limited and the relationship between the microbiome and response to radiotherapy is poorly studied.
Methods
Sixty-two patients with nasopharyngeal carcinoma scheduled for radiotherapy-based treatment were prospectively enrolled. Nasopharyngeal swab samples were collected longitudinally during radiotherapy, and their microbial composition was assessed using 16S rRNA sequencing. All patients were followed up to 24 months after completion of radiotherapy.
Results
The beta-diversity of nasopharyngeal microbial communities (np-microbiome) showed changes throughout radiotherapy-based treatment. The magnitude of changes in the np-microbiome was stably and statistically significantly different between early and late responders (P = 0.02), with greater changes in early responders. This was confirmed in a temporal network analysis, where the networks varied widely in early responders, but were significantly more constrained in late responders (P = 0.009). Operational taxonomic units (OTUs) mapped to Corynebacterrium, Staphylococcus and Anaerococcus showed increasing loss with treatment, while all other abundant OTUs were stable over treatment. Twenty-seven abundant OTUs differed statistically, significantly (P < 0.05) by patients’ response throughout the treatment period.
Conclusions
The nasopharyngeal microbiome in NPC patients changes during radiotherapy-based treatment. These changes are statistically, significantly associated with patients’ response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swedish Cancer Society; Swedish Research Council; National Natural Science Foundation of China; China Scholarship Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract